VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Name VRTXON

Rank No.3622

Market Cap $0.00

Fully Diluted Market Cap $0.00

Market Share %

Trading Vol/Market Cap (24H) 17,906,142.52%

Circulation Supply 4.00949604

Max Supply 0

Total Supply 4.00949604

Circulation Rate %

Issue Date --

The price at which the asset was first issued --

All-Time High 466.35223147502205, 2026-03-26

Lowest Price 414.92035330237934, 2026-05-05

Public Blockchain VRTXON

Introduction Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Sector

Social Media

• Twitter

• Official Website
• Block Explorer

Fund Flow Analysis

etfindex:mc_etfindex_source Disclaimer: Data provided by cmc and should not be considered as investment advice.